Outcomes after hematopoietic stem-cell transplantation for hematologic malignancies in patients with or without advance care planning

被引:33
|
作者
Ganti, Apar Kishor [1 ]
Lee, Stephanie J.
Vose, Julie M.
Devetten, Marcel P.
Bociek, R. Gregory
Armitage, James O.
Bierman, Philip J.
Maness, Lori J.
Reed, Elizabeth C.
Loberiza, Fausto R., Jr.
机构
[1] Univ Nebraska Med Ctr, Hematol Oncol Sect, Dept Internal Med, Omaha, NE 68198 USA
关键词
D O I
10.1200/JCO.2007.11.1914
中图分类号
R73 [肿瘤学];
学科分类号
100214 ;
摘要
Purpose Engagement in advance care planning (ACP) is viewed as a way to prepare for possible death. In patients undergoing hematopoietic stem-cell transplantation (HSCT), an aggressive but possibly curative procedure for cancer, encouraging engagement in ACP is difficult. We conducted this analysis to determine if engagement in ACP among patients who undergo HSCT is associated with adverse outcomes. Patients and Methods Adult patients who were undergoing their first HSCT for hematologic malignancies between 2001 and 2003 were included. ACP was defined as having a living will, a power of attorney for health care, or life-support instructions. Outcomes assessed included the length of hospital stay, in-hospital mortality, and overall survival. Results Of the 343 patients, 172 did not have ACP, whereas 171 did have ACP, and 127 of those were reviewable. Of those with reviewable ACP, 28 patients (22%) completed ACP before cancer diagnosis, 87 (68%) completed ACP after the cancer diagnosis but before HSCT, and 12 (10%) engaged in ACP after HSCT. Patients without ACP before HSCT had a significantly greater risk of death compared with patients with ACP (hazard ratio, 2.11; 95% CI, 1.34 to 3.33; P = .001) while adjusting for statistically significant factors. Conclusion Our study demonstrated that lack of engagement in ACP is associated with adverse outcomes after HSCT. Thus, the patients least likely to have planned for poor outcomes are the ones most likely to face them. Additional studies should evaluate the nature of this association and should seek modifiable explanatory factors that could be the target of interventions.
引用
下载
收藏
页码:5643 / 5648
页数:6
相关论文
共 50 条
  • [11] Allogeneic Hematopoietic Stem-Cell Transplantation in Patients With Hematologic Malignancies After Dose-Escalated Treosulfan/Fludarabine Conditioning
    Casper, Jochen
    Wolff, Daniel
    Knauf, Wolfgang
    Blau, Igor W.
    Ruutu, Tapani
    Volin, Liisa
    Wandt, Hannes
    Schaefer-Eckart, Kerstin
    Holowiecki, Jerzy
    Giebel, Sebastian
    Aschan, Johan
    Zander, Axel R.
    Kroeger, Nicolaus
    Hilgendorf, Inken
    Baumgart, Joachim
    Mylius, Heidrun A.
    Pichlmeier, Uwe
    Freund, Mathias
    JOURNAL OF CLINICAL ONCOLOGY, 2010, 28 (20) : 3344 - 3351
  • [12] Adoptive Immunotherapies After Allogeneic Hematopoietic Stem Cell Transplantation in Patients With Hematologic Malignancies
    Xiong, Yu
    Bensoussan, Daniele
    Decot, Veronique
    TRANSFUSION MEDICINE REVIEWS, 2015, 29 (04) : 259 - 267
  • [13] Relapsing Hematologic Malignancies after Haploidentical Hematopoietic Stem Cell Transplantation
    Hu, Yong-Xian
    Cui, Qu
    Liang, Bin
    Huang, He
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2011, 17 (08) : 1099 - 1111
  • [14] AUTOLOGOUS BLOOD STEM-CELL TRANSPLANTATION IN HEMATOLOGIC MALIGNANCIES
    MAJOLINO, I
    SCIME, R
    INDOVINA, A
    HAEMATOLOGICA, 1990, 75 (06) : 555 - 566
  • [15] Outcomes of patients undergoing third hematopoietic cell transplantation for hematologic malignancies
    Cox, Emily R.
    Summers, Corinne
    Milano, Filippo
    Dahlberg, Ann
    Bleakley, Marie
    Sandmaier, Brenda M.
    Thakar, Monica S.
    ANNALS OF HEMATOLOGY, 2024, 103 (09) : 3737 - 3743
  • [16] Favorable Outcomes in Patients Surviving 5 or More Years after Allogeneic Hematopoietic Stem Cell Transplantation for Hematologic Malignancies
    Le, Robert Quan
    Bevans, Margaret
    Savani, Bipin N.
    Mitchell, Sandra A.
    Stringaris, Kate
    Koklanaris, Eleftheria
    Barrett, A. John
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2010, 16 (08) : 1162 - 1170
  • [17] Advance care planning among patients undergoing hematopoietic stem cell transplantation.
    Joffe, S
    Mello, M
    Lee, S
    BLOOD, 2003, 102 (11) : 81A - 81A
  • [18] Clinical options after failure of allogeneic hematopoietic stem cell transplantation in patients with hematologic malignancies
    Petrovic, Aleksandra
    Hale, Gregory
    EXPERT REVIEW OF CLINICAL IMMUNOLOGY, 2011, 7 (04) : 515 - 527
  • [19] Advance care planning in patients undergoing hematopoietic cell transplantation
    Joffe, Steven
    Mello, Michelle M.
    Cook, E. Francis
    Lee, Stephanie J.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2007, 13 (01) : 65 - 73
  • [20] Outcomes after Second Allogeneic Hematopoietic Cell Transplantation in Adults with Hematologic Malignancies
    Huselton, Eric
    Slade, Michael
    Abboud, Camille
    Cashen, Amanda
    DiPersio, John F.
    Ghobadi, Armin
    Pusic, Iskra
    Romee, Rizwan
    Uy, Geoffrey L.
    Vij, Ravi
    Westervelt, Peter
    Schroeder, Mark A.
    BIOLOGY OF BLOOD AND MARROW TRANSPLANTATION, 2017, 23 (03) : S278 - S278